Clinical Trials
24 trialsNCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT05417386 2025-11-18
FOLFIRINOX + NIS793 in Pancreatic Cancer
Massachusetts General Hospital
Phase 1 Terminated
NCT03153280 2025-07-08
Lithium
Cancer Trials Ireland
Phase 1 Terminated
NCT02419495 2025-06-04
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02630043 2024-08-06
Trial of Tolcapone With Oxaliplatin for Neuroblastoma
Milton S. Hershey Medical Center
Phase 1 Terminated
NCT03300544 2024-05-23
Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy Before Surgery in Treating Patients With Locally Advanced or Metastatic Rectal Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03878524 2024-03-04
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
OHSU Knight Cancer Institute
Phase 1 Terminated
NCT01525069 2022-08-10
Hepatic Arterial Infusion in Treating Patients With Locally Advanced, Non-Metastatic Cholangiocarcinoma
Washington University School of Medicine
Phase 1 Terminated
NCT02384850 2022-04-08
SENTINEL
GSO Global Clinical Research BV
Phase 1 Terminated
NCT00447122 2022-03-08
BrUOG-PA-209: Lapatinib and Gemcitabine for Metastatic Pancreaticobiliary Cancer
Brown University
Phase 1 Terminated
NCT04158349 2021-09-27
IPOX-FOLFIRI
University of Utah
Phase 1 Terminated
NCT02862535 2020-12-24
Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma
Gilead Sciences
Phase 1 Terminated
NCT02648711 2020-05-28
Alternative Dosing for CRLX101(NLG207) Alone, With Avastin and With mFOLFOX6 in Advanced Solid Tumors
Lumos Pharma
Phase 1 Terminated
NCT02782182 2019-03-19
Perioperative FOLFIRINOX for Patients With Resectable Pancreatic Adenocarcinoma: A Pilot Study
University of Chicago
Phase 1 Terminated
NCT00268151 2018-03-05
Oxaliplatin in Combination With Capecitabine and Concurrent Radiation Therapy in Non-Small Cell Lung Cancer
University of Louisville
Phase 1 Terminated
NCT00356941 2017-11-29
Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT02720926 2016-03-28
Study of TKI 258 in Combination With Xeloda and Oxaliplatin in Advanced Colorectal and Gastric Cancer
National Cancer Centre, Singapore
Phase 1 Terminated
NCT01233505 2014-04-02
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00101205 2014-02-24
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00066625 2013-02-01
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00086983 2013-01-10
Rebeccamycin Analog and Oxaliplatin in Treating Patients With Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Terminated
NCT00296062 2012-01-16
Dose Dense Therapy and Bevacizumab in Solid Tumors and Colorectal Cancer
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00732745 2011-08-22
Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT01271166 2011-01-06
GlivecĀ® Plus m-FOLFOX AvastinĀ® in Advanced Colorectal Cancer
Novartis
Phase 1 Terminated